CURE Pharma Could Take Over Where Zynerba Fell Short


Ryan Allway

August 11th, 2017

News, Top News


 

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) shares fell more than 53% earlier this week after mid-stage clinical trials for its cannabidiol (“CBD”) gel in adult epilepsy patients fell short of primary and secondary endpoints. But, the results could be a boost for competitors, like GW Pharmaceuticals plc (NASDAQ: GWPH) and CURE Pharmaceutical Holding Corp. (OTCQB: CURR), which are developing similar products.

According to Leerink Partners analyst Paul Matteis, GW Pharmaceutical shares have underperformed due to the lack of clear positive catalysts in the backdrop of multiple competitive readouts. The failure of the Zynerba study reinforces the view that barriers to entry for related CBD products are high. These sentiments may also apply for smaller companies in the space, such as CURE Pharma, which is developing its own CBD products.

What’s Different?

CURE Pharma is a relatively new entrant into the pharmaceutical cannabinoid market. In May, the company announced that it had begun researching and developing proprietary formulas consisting of various cannabinoids and terpene profiles integrated into its advanced oral thin film technology, known as CureFilm™. Management has since focused on forming partnerships and collaborations with top healthcare and cannabis industry organizations around the world.

“Our goal is to bring new cannabinoid molecules to market through the FDA regulatory process, while utilizing our company’s proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options,” said CURE Pharma CEO Rob Davidson.

CureFilm™ leverages a micro-encapsulation process that protects active ingredients to enable higher dosing with better flavor masking. Unlike competing delivery systems, the technology can load multiple active pharmaceutical ingredients – or APIs – onto a single strip. The plan is to leverage the so-called entourage effect of cannabinoids while providing better bioavailability than many competing technologies to maximize safety and efficacy.

Advancing Studies

CURE Pharma has developed several partnerships with leading cannabinoid researchers to advance its clinical programs. These research agreements could help accelerate the company’s time-to-market by partnering with pharmaceutical companies developing cannabinoid-based therapies and then applying its proprietary CureFilm™ delivery system to increase the safety and efficacy profile of the drugs as they move through regulatory approvals.

In mid-July, the company announced a memorandum of understanding with Therapix Biosciences (NASDAQ: TRPX), a specialty clinical-stage pharmaceutical company dedicated to the development of cannabinoid-based drugs. The MOU entails a research collaboration with Israel’s largest and leading private medical services center, Assuta Medical Centers, Ltd., where the two companies will work to develop therapeutic products.

In late-May, the company announced that along with CannaKids, has entered into a strategic research collaboration with Technion Research and Development Foundation, Ltd., which is a wholly-owned subsidiary of the Technion-Israel Institute of Technology. The partnership will explore how different cannabinoid compounds within cannabis strains can be used to treat various cancer subtypes – a promising cutting-edge field.

Looking Ahead

CURE Pharmaceutical Research Corp. (OTCQB: CURR) is well-positioned to capitalize on the significant potential for cannabinoids to address several underlying medical conditions. Zynerba’s failure illustrates that CBD therapeutics have a high barrier to entry, but the company’s innovative delivery system promises to overcome these barriers and pave the way to long-term shareholder value creation.

For more information, visit the company’s website at www.curepharmaceutical.com.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist.


Network Partners

Follow Us on Social Media

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

Copyright © TDM Financial LLC · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading